Trials / Terminated
TerminatedNCT00683696
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,680 (actual)
- Sponsor
- Biotronik, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (\< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D) | All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2008-05-23
- Last updated
- 2018-01-17
- Results posted
- 2014-04-17
Locations
122 sites across 17 countries: United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00683696. Inclusion in this directory is not an endorsement.